Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05798156
Title Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive Large B-cell Lymphoma Ineligible for R-CHOP (R-Pola-Glo)
Acronym R-Pola-Glo
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Age Groups: adult | senior
Covered Countries DEU | AUT

No variant requirements are available.